MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 317310 | Name: Benazepril hydrochloride
Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Benazepril Hydrochloride is the hydrochloride salt of benazepril, a carboxyl-containing angiotensin-converting enzyme (ACE) inhibitor with antihypertensive activity. Benazeprilat competitively binds to and inhibits ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the potent vasoconstrictive actions of angiotensin II, resulting in vasodilation. Benazeprilat also decreases angiotensin II-induced aldosterone secretion by the adrenal cortex, which leads to an increase in sodium excretion and subsequently increases water outflow. Benazepril hydrochloride reduces blood pressure and myocardial hypertrophy in spontaneous hypertensive rats.

Chemical Structure

Benazepril hydrochloride
Benazepril hydrochloride
CAS#86541-74-4 (HCl)

Theoretical Analysis

MedKoo Cat#: 317310

Name: Benazepril hydrochloride

CAS#: 86541-74-4 (HCl)

Chemical Formula: C24H29ClN2O5

Exact Mass: 0.0000

Molecular Weight: 460.95

Elemental Analysis: C, 62.54; H, 6.34; Cl, 7.69; N, 6.08; O, 17.35

Price and Availability

Size Price Availability Quantity
1g USD 250.00 2 weeks
5g USD 550.00 2 weeks
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
86541-75-5 (free base) 86541-74-4 (HCl)
Synonym
Benazepril hydrochloride; Benazepril; Benazepril HCl; Briem; CGS-14824-A; CGS-14824A; Cibacène; Cibacen; Labopal; Lotensin
IUPAC/Chemical Name
(3S)-3-[[(1S)-1-(Ethoxycarbonyl)-3-phenylpropyl]amino]-2,3,4,5-tetrahydro-2-oxo-1H-1-benzazepine-1-acetic acid hydrochloride
InChi Key
VPSRQEHTHIMDQM-FKLPMGAJSA-N
InChi Code
InChI=1S/C24H28N2O5.ClH/c1-2-31-24(30)20(14-12-17-8-4-3-5-9-17)25-19-15-13-18-10-6-7-11-21(18)26(23(19)29)16-22(27)28;/h3-11,19-20,25H,2,12-16H2,1H3,(H,27,28);1H/t19-,20-;/m0./s1
SMILES Code
O=C(O)CN1C([C@@H](N[C@H](C(OCC)=O)CCC2=CC=CC=C2)CCC3=CC=CC=C31)=O.[H]Cl
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
Product Data
Product Data
Instruction
View handling instruction
Biological target:
Benazepril hydrochloride is an angiotensin converting enzyme inhibitor.
In vitro activity:
The effects of combination use of leflunomide and benazepril on diabetic nephropathy (DN) were investigated in vitro. Rat glomerular mesangial cells (RMCs) were treated with high-glucose (150 mg/ml) and the leflunomide and benazepril with both concentrations of 50 μmol/l were used to treat the high-glucose induced cells. Treatment of leflunomide and benazepril significantly reduced expression levels of NF-κB, TGF-β and TRPC6 in high-glucose induced RMCs. It was also observed that leflunomide and benazepril reduced high-glucose induced cell apoptosis of RMCs. Reference: Ren Fail. 2019 Nov;41(1):899-906. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6764370/
In vivo activity:
The effects of benazepril hydrochloride (BH) on proteinuria and ANGPTL-4 expression were evaluated in a diabetic nephropathy (DN) rat model. A total of 72 Wistar male rats were randomly divided into three groups: normal control (NC), DN group and BH treatment (BH) groups. Weight was significantly lower but glucose levels were significantly higher in both the DN and BH groups than in the NC group (P < 0.05). Compared with the DN group, proteinuria, urea, creatinine, triglycerides and total cholesterol levels were decreased, whereas the albumin level was increased after BH treatment (all P < 0.05). Furthermore, BH diminished kidney volume and ameliorated the pathological changes associated with DN. ANGPTL-4 expression was significantly decreased after BH treatment, and ANGPTL-4 expression was highly correlated with biochemical indicators of DN (P < 0.05). These results suggest that benazepril hydrochloride improves DN and decreases proteinuria by decreasing ANGPTL-4 expression. Reference: BMC Nephrol. 2017 Oct 4;18(1):307. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5628429/
Solvent mg/mL mM
Solubility
DMF 30.0 65.08
DMF:PBS (pH 7.2) (1:1) 0.5 1.08
DMSO 64.5 139.99
Ethanol 46.5 100.88
Water 26.0 56.47
Note: There can be variations in solubility for the same chemical from different vendors or different batches from the same vendor. The following factors can affect the solubility of the same chemical: solvent used for crystallization, residual solvent content, polymorphism, salt versus free form, degree of hydration, solvent temperature. Please use the solubility data as a reference only. Warming and sonication will facilitate dissolving. Still have questions? Please contact our Technical Support scientists.

Preparing Stock Solutions

The following data is based on the product molecular weight 460.95 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
1. Li H, Wang Y, Zhou Z, Tian F, Yang H, Yan J. Combination of leflunomide and benazepril reduces renal injury of diabetic nephropathy rats and inhibits high-glucose induced cell apoptosis through regulation of NF-κB, TGF-β and TRPC6. Ren Fail. 2019 Nov;41(1):899-906. doi: 10.1080/0886022X.2019.1665547. PMID: 31552773; PMCID: PMC6764370. 2. Xue L, Feng X, Wang C, Zhang X, Sun W, Yu K. Benazepril hydrochloride improves diabetic nephropathy and decreases proteinuria by decreasing ANGPTL-4 expression. BMC Nephrol. 2017 Oct 4;18(1):307. doi: 10.1186/s12882-017-0724-1. PMID: 28978304; PMCID: PMC5628429.
In vitro protocol:
1. Li H, Wang Y, Zhou Z, Tian F, Yang H, Yan J. Combination of leflunomide and benazepril reduces renal injury of diabetic nephropathy rats and inhibits high-glucose induced cell apoptosis through regulation of NF-κB, TGF-β and TRPC6. Ren Fail. 2019 Nov;41(1):899-906. doi: 10.1080/0886022X.2019.1665547. PMID: 31552773; PMCID: PMC6764370.
In vivo protocol:
1. Xue L, Feng X, Wang C, Zhang X, Sun W, Yu K. Benazepril hydrochloride improves diabetic nephropathy and decreases proteinuria by decreasing ANGPTL-4 expression. BMC Nephrol. 2017 Oct 4;18(1):307. doi: 10.1186/s12882-017-0724-1. PMID: 28978304; PMCID: PMC5628429.
1: Zhang Q, Ji Y, Lv W, He T, Wang J. Protective effects of leflunomide on renal lesions in a rat model if diabetic nephropathy. Ren Fail. 2015 Oct 29:1-7. [Epub ahead of print] PubMed PMID: 26512931. 2: Benazepril in dogs with asymptomatic mitral valve disease. Vet Rec. 2015 Oct 17;177(15):392. doi: 10.1136/vr.h4110. PubMed PMID: 26475899. 3: Sent U, Gössl R, Elliott J, Syme HM, Zimmering T. Comparison of Efficacy of Long-term Oral Treatment with Telmisartan and Benazepril in Cats with Chronic Kidney Disease. J Vet Intern Med. 2015 Nov;29(6):1479-87. doi: 10.1111/jvim.13639. Epub 2015 Oct 16. PubMed PMID: 26474314. 4: Gismondi RA, Bedirian R, Pozzobon CR, Ladeira MC, Oigman W, Neves MF. Renin-Angiotensin System Blockade Associated with Statin Improves Endothelial Function in Diabetics. Arq Bras Cardiol. 2015 Oct 2. pii: S0066-782X2015005050123. [Epub ahead of print] Portuguese, English. PubMed PMID: 26465872. 5: Marcondes-Santos M, Mansur AP, Fragata FS, Strunz CM. Short-term follow-up of exercise training program and beta-blocker treatment on quality of life in dogs with naturally acquired chronic mitral valve disease. Braz J Med Biol Res. 2015 Oct;48(10):886-94. doi: 10.1590/1414-431X20154568. Epub 2015 Aug 4. PubMed PMID: 26445331. 6: Mochel JP, Danhof M. Chronobiology and Pharmacologic Modulation of the Renin-Angiotensin-Aldosterone System in Dogs: What Have We Learned? Rev Physiol Biochem Pharmacol. 2015 Oct 2. [Epub ahead of print] PubMed PMID: 26428686. 7: Jenkins TL, Coleman AE, Schmiedt CW, Brown SA. Attenuation of the pressor response to exogenous angiotensin by angiotensin receptor blockers and benazepril hydrochloride in clinically normal cats. Am J Vet Res. 2015 Sep;76(9):807-13. doi: 10.2460/ajvr.76.9.807. PubMed PMID: 26309109. 8: Marcondes-Santos M, Mansur AP, Fragata FS, Strunz CM. Short-term follow-up of exercise training program and beta-blocker treatment on quality of life in dogs with naturally acquired chronic mitral valve disease. Braz J Med Biol Res. 2015 Aug 4:0. [Epub ahead of print] PubMed PMID: 26270326. 9: Qian M, Chen T, Zhou D, Zhang Z, Zhang Q, Tang S, Xiao X. Development of a new benazepril hydrochloride chewable tablet and evaluation of its bioequivalence for treatment of heart failure in dogs. J Vet Pharmacol Ther. 2015 Jul 30. doi: 10.1111/jvp.12252. [Epub ahead of print] PubMed PMID: 26228576. 10: Zhang YU, Zhou N, Wang H, Wang S, He J. Effect of Shenkang granules on the progression of chronic renal failure in 5/6 nephrectomized rats. Exp Ther Med. 2015 Jun;9(6):2034-2042. Epub 2015 Mar 24. PubMed PMID: 26136932; PubMed Central PMCID: PMC4473336. 11: Xiao X, Wang J, Chang X, Zhen J, Zhou G, Hu Z. Mycophenolate mofetil ameliorates diabetic nephropathy through epithelial mesenchymal transition in rats. Mol Med Rep. 2015 Sep;12(3):4043-50. doi: 10.3892/mmr.2015.3934. Epub 2015 Jun 15. PubMed PMID: 26080907. 12: Zhang Y, Zhou N, Li T, Wang HY, He JY. [Effect of Shenkang Injection on Kidney Function in Hypertensive Renal Damage Rats]. Zhong Yao Cai. 2014 Dec;37(12):2248-54. Chinese. PubMed PMID: 26080514. 13: Shen S, Yang X, Shi Y. Application of quantitative NMR for purity determination of standard ACE inhibitors. J Pharm Biomed Anal. 2015 Oct 10;114:190-9. doi: 10.1016/j.jpba.2015.05.021. Epub 2015 May 27. PubMed PMID: 26070161. 14: Zhu C, Luo Y. [Clinical controlled trial on chronic nephritis albuminuria treated with acupuncture and moxibustion at DONG's extra points, "Xiasanhuana"]. Zhongguo Zhen Jiu. 2015 Apr;35(4):335-8. Chinese. PubMed PMID: 26054140. 15: Jallapally A, Addla D, Bagul P, Sridhar B, Banerjee SK, Kantevari S. Design, synthesis and evaluation of novel 2-butyl-4-chloroimidazole derived peptidomimetics as Angiotensin Converting Enzyme (ACE) inhibitors. Bioorg Med Chem. 2015 Jul 1;23(13):3526-33. doi: 10.1016/j.bmc.2015.04.024. Epub 2015 Apr 16. PubMed PMID: 25922179. 16: Zou X, Zhang XX, Liu XY, Li R, Wang M, Wu WJ, Sui Y, Zhao HL. Renal kallikrein activation and renoprotection after dual blockade of renin-angiotensin system in diet-induced diabetic nephropathy. J Diabetes Res. 2015;2015:310645. doi: 10.1155/2015/310645. Epub 2015 Mar 30. PubMed PMID: 25918729; PubMed Central PMCID: PMC4397032. 17: Lee IT, Sheu WH, Hung YJ, Chen JF, Wang CY, Lee WJ. Assessment of glomerular filtration rate based on alterations of serum brain-derived neurotrophic factor in type 2 diabetic subjects treated with amlodipine/benazepril or valsartan/hydrochlorothiazide. Dis Markers. 2015;2015:780743. doi: 10.1155/2015/780743. Epub 2015 Mar 30. PubMed PMID: 25918454; PubMed Central PMCID: PMC4397057. 18: Peng DF, Tang SY, Hu YJ, Chen J, Peng X, Huang Q. Comparison of valsartan and benazepril when combined with atorvastatin in protecting patients with early cardio-renal syndrome (CRS). Eur Rev Med Pharmacol Sci. 2015 Apr;19(7):1264-71. PubMed PMID: 25912588. 19: Daina E, Cravedi P, Alpa M, Roccatello D, Gamba S, Perna A, Gaspari F, Remuzzi G, Ruggenenti P. A multidrug, antiproteinuric approach to alport syndrome: a ten-year cohort study. Nephron. 2015;130(1):13-20. doi: 10.1159/000381480. Epub 2015 Apr 21. PubMed PMID: 25895746; PubMed Central PMCID: PMC4451141. 20: Tang X, Hu X, Mei C, Yu S. Improvement of resistant hypertension by nocturnal hemodialysis in a patient with end-stage kidney disease. Case Rep Nephrol Dial. 2015 Feb 17;5(1):60-5. doi: 10.1159/000377671. eCollection 2015 Jan-Apr. PubMed PMID: 25874195; PubMed Central PMCID: PMC4376926.